Dr. Kausar Samli is a deep-tech commercialization executive with a global track record of turning frontier science—including biotechnology, quantum computing, and advanced materials—into scalable commercial solutions. He blends executive leadership, operational scale-up, corporate strategy, and capital deployment to drive enterprise value across public, private, and venture-backed environments.
Dr. Samli has held multiple C-suite and senior leadership roles navigating organizations through growth, technical complexity, and market expansion. As SVP, Global Services at Learning Machine (acquired by Hyland Software), he built and scaled global services for a secure digital credentialing platform. As COO of 1QBit, he helped steer one of the earliest quantum software companies, delivering hardware-agnostic solutions for machine learning, optimization, and simulation. As CEO of Lectenz Bio, he led the commercialization of biomarker-detection technologies powered by high-performance computing and protein engineering.
His experience spans deep-tech product development, hardware-enabled innovation, Professional Services, and SaaS, with applications in biotech/biopharma, healthcare, chemicals, cleantech, energy, natural resources, manufacturing, and digital trust ecosystems. He has led teams working with HPC, quantum and quantum-inspired devices, and next-generation computational platforms, giving him a cross-sector view of risk, regulation, and emerging-technology governance.
Dr. Samli also serves as a global advisor to executives, investors, and institutions on technology strategy, commercialization, ecosystem development, and organizational development. Having lived across Asia, the Middle East, Europe, and North America, he brings a multicultural and multilingual perspective to international expansion and cross-border innovation.
He contributes to global innovation ecosystems as an Expert for Horizon Europe, former Faculty Member at Singularity University, and an Associate at Creative Destruction Lab. He serves on corporate and non-profit boards, including Genome BC, is an ex-Marie Curie Fellow, ex-NIH awardee, and co-inventor on multiple patents.
Dr. Samli holds a Ph.D. in Biochemistry & Molecular Biology (Computational Chemistry) from the University of Georgia, an M.S. in Chemistry from Arizona State University, and a B.S. in Biochemistry from the University of Texas at Austin. He is an alumnus of Singularity University’s Global Solutions Program and a serial founder of companies commercializing nanoBio and advanced-computing technologies.
